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Key points 
Question What are the neurological manifestations of fibromuscular dysplasia (FMD).  
Findings This review describes the epidemiology, clinical and radiological manifestations, prognosis and 
management of FMD involving the cervical or intracranial arteries.  
Meaning Cerebrovascular FMD is now considered as frequent as renal FMD and longitudinal, 
international cohort studies with outcomes and genetic sequencing are needed to further understand the 
clinical course of cerebrovascular FMD and enable development of evidence-based treatments.   
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Abstract 
IMPORTANCE Data on neurological manifestations of fibromuscular dysplasia (FMD) are rare and 
current knowledge remains limited. 
OBJECTIVES To present a comprehensive review of the epidemiology, management and prognosis of 
neurological manifestations associated with cerebrovascular FMD (i.e. involving cervical or intracranial 
arteries), and to guide future research priorities. 
EVIDENCE REVIEW References were identified through searches of PubMed from inception to 
December 2017 using both the medical subject headings and text words. We also identified additional 
sources by reviewing reference lists of relevant articles and through searches of the authors’ personal 
files. We selected articles describing at least one clinical or radiological feature and/or outcome of 
cerebrovascular FMD. Isolated case reports could be included if they described interesting or noteworthy 
manifestations.  
FINDINGS We identified 84 relevant references. Diagnosis of cerebrovascular FMD is based on the 
appearance of alternating arterial dilatation and constriction (“string of beads”) or of focal narrowing, with 
no sign of atherosclerotic or inflammatory lesions. Although the radiographic diagnosis is easily apparent, 
it can be challenging in children or atypical phenotypes such as purely intracranial FMD and arterial 
diaphragm. Multiple artery involvement is common and there is increased incidence of cervical artery 
dissection and intracranial aneurysms. A variant in the PHACTR1 gene has been associated with FMD, 
as well as cervical artery dissection and migraine, although <5% of FMD cases are familial. Headaches, 
mainly of the migraine type, are observed in up to 70% of FMD patients. Cerebrovascular FMD is mostly 
asymptomatic, but most frequent neurological manifestations include transient ischemic attack (TIA) and 
ischemic stroke, notably in the presence of associated cervical artery dissection. Other devastating 
conditions include subarachnoid hemorrhage and rarely intracranial hemorrhage. Management relies on 
observational data and expert opinion. Antiplatelet therapy is estimated to be reasonable to prevent 
thromboembolic complications. Endovascular therapy is typically restricted to cases with symptomatic 
stenosis despite optimal medical therapy or in those with rupture of an intracranial aneurysm. 
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CONCLUSION AND RELEVANCE Longitudinal cohort studies of multiple ethnicities with biosampling are 
needed to better understand risk factors, pathophysiology, and outcomes. Patient advocacy groups could 
assist researchers in answering patient centered questions with FMD.  
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Introduction 
Fibromuscular dysplasia (FMD) is an idiopathic, noninflammatory, nonatherosclerotic vascular disease of 
small- to medium-sized arteries.1,2 In FMD patients, the frequency of involvement of cervical (carotid and 
vertebral) and intracranial arteries is higher than previously thought and as common as those of renal 
artery but data on neurological manifestations of FMD (or cerebrovascular FMD) remain rare.1,3,4 Although 
generally considered a benign entity when discovered incidentally, cerebrovascular FMD can lead to 
potentially devastating cerebrovascular complications, including ischemic and hemorrhagic stroke.3,5,6 
Also, more than half of patients with cerebrovascular FMD have concomitant lesions in the renal artery, 
which implies that they are exposed to additional potentially severe renal complications, including 
hypertension, preeclampsia and renal infarction.1,3,4 This review summarizes data on cerebrovascular 
FMD, along with a proposal for future research priorities.  
 
Methods  
Search Strategy 
We searched studies indexed in PubMed using the MeSH term “fibromuscular dysplasia” or the text 
words “fibromuscular dysplasia” OR “fibromuscular hyperplasia” until December 31, 2017, with no 
language restrictions. We also identified additional studies through searches of the authors’ personal files. 
We included articles describing at least one aspect of epidemiology, clinical characteristics, radiological 
features, or outcomes of cervical or intracranial FMD, and preferentially focused on studies published 
within the last 5 years and those including ³15 patients. However, case reports or small case series 
describing interesting or noteworthy manifestations could be included. When publications involved 
overlapping study samples, only the largest and most recent one was included unless in the case of 
description of new parameter or additional relevant data. The quality of evidence was rated according to 
the Oxford Centre for Evidence-Based Medicine levels of evidence.7 
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Results  
Of the 2788 articles identified through PubMed and the 16 from hand searching, screening and eligibility 
assessment led to the inclusion of 84 studies (eFigure 1 in the Supplement). Studies were mainly case 
series or retrospective studies, with therefore a low quality of evidence (eTable 1).  
  
Classification and diagnostic criteria  
The historical classification for FMD has focused on arterial wall involvement (medial, intimal and 
adventitial subtypes).1 However, in clinical practice, histological specimens are rarely obtained and 
diagnosis is most commonly based on radiological findings. Therefore, the European consensus 
statement and the American Heart Association (AHA) scientific statement on FMD have described a 
new classification based on angiographic appearance to replace the histopathological classification 
(Table).1,2  
 
Imaging 
High level evidence data on imaging modalities for the diagnosis of cerebrovascular FMD are lacking, 
and no imaging modality can be recommended over another. Preferred techniques for computerized 
tomography-angiography (CTA) and magnetic resonance angiography (MRA) are described in the 
Online-Only Materials. 
Digital subtraction arteriography remains the gold standard for diagnosis of FMD, due to its higher 
sensitivity than CTA or MRA (Figures 1, 2, eFigures 2,3).2,8,9 However, because of the risk of iatrogenic 
dissection with conventional arteriography (which may be higher in FMD patients than in the general 
population), its use is typically restricted to severe cases requiring endovascular management while 
CTA or contrast-enhanced MRA are commonly used as the initial imaging modality in most centres. 
Duplex ultrasound may be used to diagnose and monitor patients with FMD involving the extracranial 
carotid arteries but is less accurate than CTA or MRA (Figure 3) and inadequate for the assessment of 
vertebral or intracranial arteries.10  
 
FMD primarily occurs in the cervical portion of the carotid and vertebral arteries while intracranial FMD 
is rare, usually extending from extracranial FMD or as the predominant location of FMD subtypes in 
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children.5 Cerebrovascular FMD typically involves the middle and distal portions of the internal carotid 
artery and the V3/V4 segment of vertebral arteries at the level of the C1 and C2 vertebrae, areas which 
are usually spared by atherosclerosis. 
 
Epidemiology  
As in patients with renal FMD, cerebrovascular FMD is much more common in women and typically 
becomes symptomatic in the 5th decade (eTable 2). There is typically no family history with <5% of 
patients reporting an affected family member.3-5  
The role of hormonal factors in the development of FMD remains uncertain and case-control studies have 
found no association between FMD and gravidity or exogenous hormone exposure.1 Although smoking 
has been reported to be associated with renal FMD,1 no similar data exist for cerebrovascular FMD.11 
However, smoking and hormonal factors are associated with aneurysm growth and may therefore 
influence the risk of stroke in FMD patients.12,13  
 
The prevalence of cerebrovascular FMD in the general population is unknown. Only 0.02% of consecutive 
autopsies performed at the Mayo Clinic over a period of 25 years detected FMD of the internal carotid 
artery.14 Several studies suggest that the frequency of involvement of a cervical artery is now as frequent 
as those of renal artery.3,15 Cerebrovascular FMD affects the carotid artery (often bilaterally) in 95% of 
cases and the vertebral artery (usually with co-involvement of the carotid) in 60-85% of cases.5 Also, 
multiple locations, especially in the multifocal form but not only, are considered more common than 
previously thought. In the US Registry, renal artery involvement was reported in 64% of patients with 
cervical FMD while cervical FMD lesions were found in 65% of patients with renal artery FMD.3 In the 
ARCADIA Registry, where assessment for multisite involvement was systematic, the prevalence of 
multisite locations was 48% in FMD patients and 54% in those with cerebrovascular presentation. Also, 
among FMD patients with cerebrovascular presentation, the prevalence of renal artery FMD involvement 
was three times higher with a history of hypertension, suggesting that history of hypertension could help 
identify patients who may benefit from screening for renal FMD.4 Data on prevalence of involvement of 
other arterial beds (e.g. brachial, celiac, iliac, and coronary) in cerebrovascular FMD patients are 
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scarce.1,15 While FMD is rarely reported in the coronary arteries,16 a strong association between FMD and 
spontaneous coronary artery dissection (SCAD) has been recently identified, with a high prevalence of 
extra-coronary FMD lesions in SCAD patients.17 In a large series of SCAD patients (n=168), cervical FMD 
and intracranial aneurysms were detected in 52% and 14% of cases, respectively.18 In patients with 
cerebrovascular FMD, although prevalence of SCAD is very low, silent coronary lesions may exist, 
however the cost-effectiveness of screening for associated coronary artery disease is unknown and 
screening is not recommended.  
 
Genetic Risk 
Heritability estimates of FMD are challenging due to the frequency of an asymptomatic phenotype and the 
lack of accurate characterization in family histories. Several candidate gene studies of FMD have been 
negative or have only been positive in isolated case reports (eTable 3),13 and genome-wide association 
studies are lacking. While FMD shares some phenotypic features with monogenic connective tissue 
diseases such as Marfan’s, Ehlers-Danlos, and Loeys-Dietz syndromes, systematic screening of genes 
mutated in these syndromes failed to yield associations with FMD.19,20 Whole exome sequencing analysis 
in 16 FMD patients from 7 families found no gene variants shared among all affected sib-pairs.21 Large-
scale studies using low density exome chip arrays have identified an intronic variant (rs9349379) in the 
PHACTR1 gene (6p24) as a first susceptibility locus for FMD, with an increased risk of ~40% among risk 
allele carriers.22 Interestingly, this same risk allele has previously been associated with migraine and 
cervical artery dissection, and has recently been found to regulate the expression of endothelin-1 with 
known physiologic effects on the systemic vasculature.23  
 
Presenting manifestations 
Although cerebrovascular FMD is frequently asymptomatic and diagnosed incidentally on imaging 
obtained for other indications, the most common presenting symptoms are headaches and pulsatile 
tinnitus.3,4 Compared to the general population, FMD patients have a high prevalence of associated 
cervical (carotid or vertebral) artery dissection and intracranial saccular aneurysm.5,24 The main 
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complications of cerebrovascular FMD are transient ischemic attack (TIA) or ischemic stroke, followed by 
subarachnoid hemorrhage and intracerebral hemorrhage (eTable 2).  
 
Headaches are reported by 70% of patients with cerebrovascular FMD with 30% suffering from 
migraine.3,4,15 Despite the high co-prevalence of headaches and migraine with cerebrovascular FMD, the 
underlying pathophysiology remains unclear. Possible mechanisms include alterations in cerebrovascular 
flow (e.g. labile hypertension, hyper- or hypoperfusion), neurovascular dysregulation or dysautonomia, 
structural injury (e.g. dissection, microtrauma), or heightened pain sensitivity.25  
 
Carotid bruit (the most common presenting sign of cervical FMD) or/and pulsatile tinnitus, often 
described by patients as an auditory “whooshing”, are observed in up to 40% of patients with cervical 
FMD.3 Less frequently reported symptoms include neck pain/carotidynia, blurry vision, and dizziness, the 
latter being described mostly as light-headedness or presyncope as opposed to vertigo. These 
nonspecific symptoms may represent manifestations of fluctuating blood pressure, persistent migraine 
aura, or dysautonomia secondary to neurovascular disruption in the vessel wall. In rare cases, light-
headedness may be due to cerebral hypoperfusion related to severe multi-vessel cerebrovascular FMD. 
 
Cervical artery dissection: Recent data from the US registry have shown that the prevalence of carotid 
and vertebral artery dissections in all patients with FMD is estimated to be 16% and 5%, respectively. 
Among FMD patients who experience a dissection, the carotid artery is the most frequently involved 
(64%), followed by the vertebral artery (21%), and prevalence of multiple cervical dissections is high (up 
to 37%).3 Among FMD patients with a neurological presentation in the ARCADIA registry, the prevalence 
of cervical dissection was 27%.4 Concomittantly, studies of individuals with cervical artery dissection 
report that the prevalence of cervical FMD may be as high as 15-20%,13,26 and is increased in the 
presence of multiple cervical dissections.27  
Cervical dissection is most often seen in the mid to distal segments of the extracranial internal carotid 
artery and vertebral arteries, where traction on the arteries is maximal. Extension and lateral rotation of 
the head and neck enhance stretching of the cervical arteries, and this may play a role in the association 
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between FMD and cervical dissection but whether these mechanical factors are involved in the etiology of 
cerebrovascular FMD remains speculative.5  
 
Intracranial saccular aneurysms are mainly unruptured and diagnosed incidentally on imaging rather 
than discovered after rupture. A meta-analysis of over 500 cerebrovascular FMD patients reported a 
prevalence of unruptured intracranial aneurysm of 7%, which was higher than that expected in the 
general population (<5%).28 In the US Registry, 13% of women with FMD had at least one intracranial 
aneurysm and 4% more than one. Interestingly, 29% of these aneurysms were of size ≥5mm, which is the 
threshold usually considered to classify intracranial aneurysms with a higher risk of rupture.29 Also, there 
was no difference in the prevalence of intracranial aneurysms between patients with renal and cervical 
FMD.30  
Whether the risk of rupture of intracranial aneurysm is higher in FMD patients that in the general 
population (<1%/year) remains uncertain. 
 
TIA or ischemic stroke in FMD patients can result from different mechanisms: hypoperfusion from 
cervical or intracranial arterial stenosis or occlusion (hemodynamic mechanism); emboli from a 
thrombosis in the area of a stenosis or dilation; or via thrombosis of small, perforating arteries due to 
chronic hypertension secondary to the coexistence of renal FMD (lacunar stroke). However, TIA/ischemic 
stroke seem to occur mainly in the presence of associated cervical artery dissection, due to artery-to-
artery thromboembolism or cerebral hypoperfusion. In the US registry, 10% of FMD patients presented 
with ischemic stroke and 20% with TIA.3  
 
Intracerebral hemorrhage is rare in patients with FMD but can occur in the presence of hypertensive 
microangiopathy or from the rupture of an intracranial aneurysm or dissection.5  
 
Subarachnoid hemorrhage mainly results from the rupture of an intracranial aneurysm and less 
commonly from dissecting vertebral artery into the intracranial segment.5 The prevalence of subarachnoid 
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hemorrhage is estimated to be 3% in all FMD patients and 20% among those who present with acute 
neurological manifestations.4  
 
Specific subtypes 
Purely intracranial FMD 
Purely intracranial FMD seems rare and more frequent in children than adults.5,31 Although intracranial 
FMD most often corresponds to the extension of extracranial cervical FMD,5 isolated intracranial FMD 
with a typical “string of beads” angiographic appearance in the basilar artery, distal internal carotid artery, 
and middle cerebral artery has also been reported.5 Additionally, autopsy reports of patients with fatal 
intracranial artery dissection or aneurysmal subarachnoid hemorrhage have shown histologic evidence of 
FMD.5,32 Histologic evidence of FMD has also been reported in fusiform or dolichoectactic intracranial 
artery,33,34 moya-moya syndrome and carotid-cavernous fistula.5 While FMD of extracranial arteries 
typically involves the medial layer of the vessel wall, intracranial FMD predominantly involves the intima, 
suggesting a genotype-phenotype variation by anatomical location in the cerebrovascular vasculature. 
 
Cerebrovascular FMD in children 
A recent study combining a large serie of new cases with the existing literature (totalling 81 cases) 
showed that cerebrovascular FMD in children (birth to 18 years) differs from adults in clinical and 
histological characterisics.31,35 Both genders are equally affected and most cases are diagnosed early in 
childhood (mean age of 7 years), with a third being diagnosed in the first year of life. Focal FMD with 
intimal fibroplasia pathology seems to be the predominant form while the more typical adult appearance 
of multifocal FMD (medial fibroplasia) is estimated to be very rare.31 Associated moya-moya syndromes 
and intracranial aneurysms, have also been reported. Systemic FMD occurred frequently in children, with 
63% having renal FMD and 72% having an additional arterial bed involvement.31 Ischemic stroke appears 
to be the predominant presentation (63% of cases), mainly due to intracranial stenosis, and affecting 
multiple territories (40%). The outcome remains poor with a high annual rate of recurrent stroke (10%) 
and death (13%).31  
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Carotid bulb diaphragm 
An entity called “arterial diaphragm” or “web” was reported to share similar histological findings with FMD, 
with intimal fibroplasia without atheromatous or inflammatory lesions being described in almost all cases 
treated by surgery.5,36,37 Several authors estimate that this could be the predominant form of FMD in 
Black populations and have classified it as “atypical FMD”.38 Arterial diaphragms are thin translucent 
endoluminal webs located in the carotid (especially in the posterolateral side of the carotid bulb) or 
vertebral (V3 segment or ostium) artery and correspond to a linear defect on angiography that do not 
change or disappear after modification of the patient’s head position (Figure 4).39-41 Since its first 
description in 1967,42 >50 cases have been reported. Diaphragms typically affect middle-aged adults, 
predominantly women, of African or Afro-Caribbean ethnicity, with no atherosclerotic risk factors.36 The 
main clinical presentations are TIA or ischemic stroke ipsilateral to the diaphragm and a strong 
association between carotid bulb diaphragm and ischemic stroke has been reported in a population-
based case-control study.38 Cerebral ischemia is estimated to be mediated by an embolic mechanism, 
because of stasis upstream to the web or within an associated aneurysmal bulb, or from focal dissection. 
In the presence of TIA/ischemic stroke, the rate of recurrent ischemic events in the same territory seems 
particularly high on antiplatelet therapy, up to 30% at 1 year in the largest cohort.36 In case of recurrent 
ischemic events despite medical management, diaphragm exclusion with endarterectomy36 or stenting43 
has been proposed. The largest cohorts of patients undergoing diaphragm exclusion by either method 
(n=25) reported no recurrences after a follow-up of 1-2 years. In several cases, carotid diaphragm was 
associated with the presence of an aneurysmal bulb (sometimes called megabulb),37,44 which may also 
contribute to the risk of cerebral thromboembolism. 
 
Management  
In the absence of randomized trials in cerebrovascular FMD, current medical and interventional strategies 
rely on observational data and expert opinion. Because of the high prevalence of aneurysms and 
dissections in other arterial beds (including renal and aortic branch arteries), patients diagnosed with 
cerebrovascular FMD should undergo a head to pelvic vascular imaging. 
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Cerebrovascular FMD without stroke complications 
In the presence of FMD without stroke complications, including associated asymptomatic cervical 
artery dissection, daily low dose aspirin (75-100 mg/day) is a reasonable choice to prevent thrombo-
embolic complications, with little evidence to suggest that alternative antiplatelet agents or combination 
therapy offers additional benefit for primary stroke prevention.1 Because of the prevalent involvement of 
other arterial beds, a multidisciplinary approach should be utilized.2 Hypertension, which is commonly 
observed in FMD patients, either due to essential or associated renal artery involvement, needs to be 
controlled. Data comparing antihypertensive therapies in FMD patients with hypertension are lacking and 
uncertainties remain about which drugs work best in this population. Current guidelines on hypertension 
should therefore be followed.45  
In view of the high prevalence of unruptured intracranial aneurysm, FMD patients should also be 
encouraged to quit smoking, but no data are available in the literature to recommend one method on the 
others. Observational studies of patients with cervical artery dissection suggest an inverse relationship 
between dyslipidemia and risk of dissection, in contrast to patients with atherosclerotic disease.46 
Therefore, statins are not recommended for FMD patients, unless to treat co-prevalent dyslipidemia or 
atherosclerotic disease. Surgical or endovascular therapy is not recommended for patients with 
asymptomatic carotid FMD, regardless of the severity of stenosis.47 Patients should likely avoid 
chiropractic spinal manipulation and other activities involving rapid hyperextension or lateral rotation of 
the neck due to the theoretical increased risk of cervical dissection.48  
 
Migraine and pulsatile tinnitus 
Although migraine is a common and potentially disabling disorder, no studies have assessed 
interventions for migraine in FMD patients. Whether typical treatment response differs in FMD patients, or 
whether certain classes of pharmacotherapy may have specific effects in FMD-related migraine remains 
unknown. Similar medical management as in the general population is recommended, although abortive 
triptan therapy or other sympathomimetic agents should be used with caution due to the potential for 
vasoconstriction.25 Some studies suggest that patients with incapacitating pulsatile tinnitus might benefit 
from psychological therapies,49 although none of these studies focused on patients with FMD.  
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Unruptured intracranial aneurysm 
In the shortage of data on predictors of rupture of intracranial aneurysm in FMD patients, similar 
management as in the general population should be proposed. Securing an unruptured intracranial 
aneurysm (by surgical clipping or endovascular coiling) might be discussed in the presence of risk factors 
for rupture.29  
Concern has been raised about the use of antiplatelets in FMD patients because of the high prevalence 
of intracranial aneurysm. There are insufficient data to establish an association between antiplatelet use 
and risk of rupture of intracranial aneurysm29 and its use seems reasonable in FMD patients with a small 
unruptured intracranial aneurysm. Patients with unruptured intracranial aneurysms who did not undergo 
an intervention are often monitored with non-invasive imaging, but predictors of aneurysm growth remain 
unclear and the optimal frequency of follow-up is unknown.50  
 
Cerebrovascular FMD with stroke complications 
In FMD patients with TIA/ischemic stroke due to arterial stenosis or dissection, management should be 
similar to that of patients without FMD.51 In the acute phase, intravenous thrombolysis and/or mechanical 
thrombectomy are recommended in eligible patients while an antithrombotic agent is to be prescribed in 
patients non eligible for intravenous thrombolysis.26,52 Secondary prevention of TIA/ischemic stroke 
should be tailored to the underlying stroke mechanism. Long-term antithrombotic therapy is 
recommended but statins are not indicated in the absence of dyslipidemia or vascular atherosclerotic 
disease.53 Endovascular therapy (e.g. carotid angioplasty +/- stenting) is typically restricted to cases with 
persistent cerebrovascular ischemia despite optimal medical therapy,52,54,55 while dissecting aneurysms 
(i.e. pseudoaneurysms) are at low risk of ischemic events or rupture and rarely require endovascular 
treatment.56,57 If an endovascular intervention is indicated, careful attention should be made to avoid 
iatrogenic vascular injury during groin access or guide catheter placement. However, whether 
cerebrovascular FMD increases the risk of iatrogenic dissection or post-stenting pseudoaneurysm 
development is unknown.  
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The management of intracerebral hemorrhage and aneurysmal subarachnoid hemorrhage in 
patients with FMD does not differ from that in those without.58,59  
There is limited evidence for endovascular or surgical treatment in cases of intracranial dissection,60 or 
moya-moya syndrome in the setting of cerebrovascular FMD.61  
 
 
Prognosis 
Given the lack of high quality population-based data, the risk of incident and recurrent stroke in patients 
with cerebrovascular FMD remains uncertain. Longitudinal studies of cerebrovascular FMD patients (the 
majority of whom presented with TIA or ischemic stroke) reported a risk of TIA/ischemic stroke during 
follow-up between 0.6% and 3.7%/year and of intracerebral hemorrhage <1%/year6,62-67 (eTable 4). Risk 
of FMD progression in cervical/intracranial arteries was estimated to be <1%/year, but no systematic 
imaging screening was performed in these studies.6,65,67 Looking at the most recent (>2015) studies of 
patients with cervical FMD, totalling approximately 100 cases (53% with previous TIA or stroke), the risk 
of all stroke or TIA during follow-up was <0.5%/year.6,67 Interestingly, all except one patient with a follow-
up event had a previous stroke and none had a progression of FMD in the previously affected artery. 
Data from the US registry suggest that TIA/ischemic stroke occur mainly in patients with an associated 
cervical dissection.3  
In the absence of stroke complications, the prognosis of isolated cerebrovascular FMD appears relatively 
favourable although cases of cerebrovascular events have been reported in previously unaffected arteries 
but data on risk factors for FMD progression are lacking.3,4 
 
Discussion and future directions 
Despite advancements in clinical and radiological characterisation of FMD over time, significant 
knowledge gaps remain which should foster clinical and pathophysiological research in the neurological 
manifestations of FMD. International research collaborations as long as inclusion of patients in registries 
should be promoted to gain knowledge of the mechanisms and evolution of FMD and to raise awareness 
	 18 
among clinicians and patients about this potentially disabling condition. Box presents what, we believe, 
the research priorities specific to cerebrovascular FMD should be.  
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Table – Angiographic Classification of Fibromuscular Dysplasia (FMD) with two categories: focal 
and multifocal1,2  
 
 Multifocal FMD Focal FMD 
Angiographic 
appearance 
• Alternating arterial dilatation and 
constriction (“string of beads” 
appearance) 
• Areas of dilatation are larger than 
the normal calibre of the artery 
• Commonly occurs in the middle or 
distal portion of the artery 
 
• Unifocal concentric (< 1cm in 
length) or tubular (≥ 1cm) 
smooth narrowing * 
• Can occur in any portion of the 
artery 
Histology • Medial fibroplasia (most common) 
Involves a functional transformation 
in smooth muscle cells of the 
arterial media, ultimately 
associated with plurifocal medial 
fibroplasia, attenuation of elastic 
fibres, and abnormal collagen 
synthesis.13 
• Perimedial fibroplasia (rare)‡ 
• Intimal fibroplasia (most 
common) 
• Adventitial (periarterial) 
fibroplasia (rare) 
• Medial hyperplasia (rare) 
Frequency • 90% • 10%  
(unifocal FMD: <10% and 
tubular FMD: <1%) 
Associated features Aneurysm, dissection, and tortuosity of medium-sized arteries may be 
present, but their presence alone is insufficient to diagnose FMD. 
Multifocal and focal lesions may coexist in the same patient (20%). 
 
* There may be multiple areas of focal disease (e.g. carotid and vertebral artery) in the same patient. 
‡This rare form of FMD typically occurs in young girls (e.g. 5 to 15 years of age). Although there is a 
beaded appearance to the renal arteries, the beads are smaller than the normal renal artery and less 
numerous. 
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Figure 1 – Multimodal imaging of the same vessel of a typical multifocal cervical fibromuscular 
dysplasia  
 
A. Computerized tomography-angiography (CTA), volume rendering reconstruction of a left cervical 
internal carotid artery with string of beads appearance.  
B. CTA, maximum intensity projection reconstruction of the same artery.  
C. Oblique projection of conventional angiography.  
D. 3D T1 contrast enhanced magnetic resonance angiography (MRA) in maximum intensity projection 
reconstruction.  	
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Figure 2 - Cervical fibromuscular dysplasia (FMD) associated with intracranial aneurysms 
 
A. Coronal view of a Maximum Intensity Projection (MIP) on a tridimensional Time of Flight sequence MRI 
of a patient harboring a cervical FMD associated with intracranial aneurysms (doted white arrows).  
B. Antero-posterior angiogram of a left internal carotid artery on the same patient showing more details of 
this intracranial form.  
C. Antero-posterior angiogram of a left internal carotid artery in a different patient, showing on the same 
image the large intracranial aneurysm and cervical fibromuscular dysplasia (black arrow head).  	
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Figure 3 – Typical duplex ultrasound findings of carotid fibromuscular dysplasia (FMD) 
 
The string of beads appearance, (visualised by multiple areas of focal hyper-echoic thickening of the 
arterial wall alternating with thin dilated areas), is not commonly seen on ultrasound.4 Visualization of the 
beading, when present, can be facilitated by the use of three dimensional color doppler.5 Common 
ultrasound findings include a combination of increased velocity of blood flow, tortuosity, and turbulence in 
the mid to distal internal carotid artery.6 
 
A. B-mode imaging showing the beading and tortuosity of the mid and distal internal carotid artery.  
B. Color Doppler of the distal internal carotid artery exhibiting the typical pattern of tortuosity and marked 
turbulence.  
C. Color Doppler showing turbulence and spectral analysis demonstrating high peak velocity (419 cm/s) 
and end-diastolic velocity (186 cm/s). The "seagull" (yellow arrow) indicates that the stenosis is quite 
severe.  
D. Color power angiography demonstrating severe tortuosity and redundancy (S curve) of the internal 
carotid artery.   
From Olin JW, Gornik HL, Bacharach JM et al.  Circulation 2014;129:1048-1078. 	
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Figure 4 – Carotid Bulb Diaphragm form of fibromuscular dysplasia (FMD)  
A. Conventional angiography of an internal carotid artery, showing a thin translucent endoluminal 
diaphragm (black arrow).  
B. Regular and thin intraluminal filling defect on an oblique reconstruction of cervical computerized 
tomography-angiography (CTA) (white arrow).  
C. Axial appearance on the same exam (white dotted arrow).  
D. Another example of carotid diaphragm on conventional angiography (black arrow).  
E. Macroscopic view of carotid bulb diaphragm: focal and non-circumferential thin membrane (white 
arrow) located on the posterior wall of the carotid bulb. The relationship of this entity to multifocal or focal 
fibromuscular dysplasia remains uncertain. 
 
		 	
	 28 
Box – Proposal for future research priorities in cerebrovascular fibromuscular dysplasia (FMD) 
 
- Better determine the natural history of cerebrovascular FMD, identify risk factors for 
cerebrovascular complications, and to address optimal symptomatic and preventive management 
in cerebrovascular FMD. Also, more research is needed to risk-stratify asymptomatic/benign FMD 
phenotypes from more severe types with more disabling symptoms or higher risk for stroke or 
associated cervical artery dissection or intracranial aneurysm formation. Prospective randomized 
controlled trials are warranted in cerebrovascular FMD but limited by the relatively small numbers 
of cases at single centers. Therefore, multicentre trials or expanded prospective registries remain 
a top research priority. Apart from the US and the European registries, others have been 
implemented in Argentina, Australia, China, Japan, and Tunisia and strategies to raise awareness 
of the existence of these registries should be facilitated to help increase our collective knowledge. 
The French research programs ARCADIA and PROFILE are currently addressing the co-
prevalence of cerebrovascular and renal FMD and the risk of clinical or radiological progression in 
a cohort of about 500 patients.4  
- To provide further insight, beyond the PHACTR1 locus, into the genetics and physiopathology of 
FMD and associated cerebrovascular phenotypes, including migraine, cervical artery dissection, 
and intracranial aneurysm. We also need better pathophysiological understanding of the 
mechanism of disease mediated by the PHACTR1 locus on downstream endothelin expression 
and physiology in the arterial wall. Genetic data collection should be more promoted among 
clinicians and patients to allow further sequencing studies. 
- Characterization of the mechanisms of migraine and/or headaches in cervical FMD as well as to 
identify which treatment strategies are safe and likely to be the most beneficial.  
- To elucidate whether there is an inflammatory or hormonal role in the development, progression 
and management of cervico-cephalic FMD 
- Determination of additional research priorities that are important to patients with cerebrovascular 
FMD, utilizing patient advocacy groups. 
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eTable 1 – Evidence level of studies evaluating epidemiology, genetic risk, presenting 
manifestations, cerebrovascular clinical manifestations, management and prognosis in 
neurological manifestations of fibromuscular dysplasia: summary of systematic review 
according to the Oxford Centre for Evidence-based Medicine 
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eTable 3 – Genetic investigations and syndromic reports of fibromuscular dysplasia  
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inclusion of studies in the systematic review 
 
eFigure 2 – Mild cervical and focal form of fibromuscular dysplasia (FMD)  
 
eFigure 3 – Illustrative clinical case of diffuse fibromuscular dysplasia (FMD) in a 
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Description of the preferred techniques for computerized tomography-angiography 
(CTA) and magnetic resonance angiography (MRA) and common findings on 
ultrasound in cerebrovascular fibromuscular dysplasia (FMD) 
 
Computerized tomography-angiography (CTA) 
The preferred technique for CTA includes contrast bolus injection with bolus-tracking acquisition that allows 
for detection of luminal defects and arterial wall dysplasia.1 Post-processing is a helpful tool in the diagnosis of 
fibromuscular dysplasia (FMD) involving the cervico-encephalic arteries, including volume rendering, 
maximum intensity projection, and multi planar reconstruction.  
 
Magnetic resonance angiography (MRA) 
Several acquisition techniques and protocols for MRA (such as “time-of-flight”, contrast enhanced time-of-flight, 
or 3D contrast enhanced fast spin echo) are available but none of these sequences have been compared to one 
another for the diagnosis of cerebrovascular FMD. However, dynamic contrast enhancement is recommended to 
reduce artifact due to turbulence and flow modification.1,2 Like CTA, post-processing tools of MRA may further 
assist in the diagnosis for mild or focal forms of cervico-cephalic FMD (efigure 2). 
 
Duplex ultrasound  
Duplex ultrasound may be used to diagnose and monitor patients with FMD involving the extracranial carotid 
arteries but is less accurate than CTA or MRA (Figure 3). Ultrasound is also inadequate for the assessment of 
vertebral or intracranial arteries.3The string of beads appearance, (visualised by multiple areas of focal hyper-
echoic thickening of the arterial wall alternating with thin dilated areas), is not commonly seen on ultrasound.4 
Visualization of the beading, when present, can be facilitated by the use of three dimensional color doppler.5 
Common ultrasound findings include a combination of increased velocity of blood flow, tortuosity, and 
turbulence in the mid to distal internal carotid artery (ICA).6 
 
 
References 
1. Varennes L, Tahon F, Kastler A, et al. Fibromuscular dysplasia: what the radiologist should know: a 
pictorial review. Insights into imaging. 2015;6(3):295-307. 
2. Persu A, Giavarini A, Touze E, et al. European consensus on the diagnosis and management of 
fibromuscular dysplasia. Journal of hypertension. 2014;32(7):1367-1378. 
3. Arning C, Grzyska U. Color Doppler imaging of cervicocephalic fibromuscular dysplasia. 
Cardiovascular ultrasound. 2004;2:7. 
4. Zhou W, Bush RL, Lin PL, Lumsden AB. Fibromuscular dysplasia of the carotid artery. Journal of the 
American College of Surgeons. 2005;200(5):807. 
5. Chehab BM, Gupta K. Contemporary diagnosis of carotid fibromuscular dysplasia: role of power 
Doppler and a review of other diagnostic modalities. Reviews in cardiovascular medicine. 2013;14(2-
4):e136-143. 
6. Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical 
unanswered questions: a scientific statement from the American Heart Association. Circulation. 
2014;129(9):1048-1078. 
 
  
 3 
eTable 1 – Evidence level of studies evaluating epidemiology, genetic risk, 
presenting manifestations, cerebrovascular clinical manifestations, 
management and prognosis in neurological manifestations of fibromuscular 
dysplasia according to the Oxford Centre for Evidence-based Medicine.  
 
Quality Rating Scheme for Studies and Other Evidence according to the Oxford Centre for 
Evidence-based Medicine (https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-
levels-evidence-march-2009/): 
  
1. Properly powered and conducted randomized clinical trial; systematic review with meta-analysis 
2. Well-designed controlled trial without randomization; prospective comparative cohort trial 
3. Case-control studies; retrospective cohort study 
4. Case series with or without intervention; cross-sectional study 
5. Opinion of respected authorities; case reports 
 
Manuscript sections Number of studies included by evidence level 
Classification and 
diagnostic criteria 
- 1 Level 4 study (Southerland, 2013)1 
- 2 guidelines/statements (Persu, 2014; Olin, 2014)2,3  
Imaging - 3 level 4 studies (Touzé, 2010; Varennes, 2015; Zhou, 2005)4-6 
- 1 level 5 study (Arning, 2004)7 
- 1 guideline/statement (Persu, 2014)3 
Epidemiology - 7 Level 3 studies (Schievink, 1996; Olin, 2012; Saw, 2013; Saw, 
2014; O’Connor, 2016; Plouin, 2017)8-13 
- 2 level 4 studies (Pasquini, 2015; Southerland, 2013)1,14  
- 2 Level 5 studies (Touzé, 2010;Camuglia, 2008)6,15  
- 1 guideline/statement (Olin, 2014)2 
Genetic risk - 5 Level 3 studies (Bofinger, 2000; Bofinger, 2001; Poloskey, 2012; 
Kiando, 2015; Kiando, 2016)16-20  
- 5 level 4 studies (Schievink, 1996; Grimbert, 1998; Marks, 2011; 
Southerland, 2013; Gupta, 2017)1,21-24 
- 7 Level 5 study (Fleischer, 1978; Kousseff, 1989; Lancman, 1991; 
Schievink, 1994; Schievink, 1994; Solder, 1997; Ganesh, 2014)25-30  
Presenting and 
cerebrovascular clinical 
manifestations 
- 33 Level 3 studies (Houser, 1971; Ehrenfield, 1974; Manelfe, 1974; 
Osborn, 1977; Boudin, 1977; Effeney, 1980; Corrin, 1981; So, 1981; 
Collins, 1981; Wells, 1982; Mettinger, 1982; Kelly, 1982; Stewart, 
1986; Wesen, 1986; Moreau, 1993; Cloft, 1998; Liu, 2012; Olin, 2012;  
Kirton, 2013; Debette, 2014; Béjot 2014; Joux, 2014; O’Connor, 2015; 
Pasquini, 2015;  Choi, 2015;  Kadian-Dodov, 2016; Joux, 2016; Green 
2016; Hariott, 2017; Plouin, 2017; Haussen, 2017;  Lather, 2017; de 
Groote, 2017)8,9,14,31-60 
- 8 Level 4 studies (Belen, 1996; Faggioli, 1996; Nakamura, 2000; 
Kubis, 1999; Southerland, 2013; Lenck, 2014; Touzé, 2010; Ukkola-
Pons, 2012)1,6,36,61-66  
- 2 Level 5 studies (Choi, 2014; van de Nes, 2017)67,68 
Management - 3 level 3 studies (O’Connor, 2015; Debette, 2014; Larsson, 
2017)50,69,70  
- 2 level 4 studies (Touzé, 2001; Schirmer, 2011)71,72 
- 3 Level 5 studies (Debette, 2009; Debette, 2015; Hage, 2015)69,73,74 
- 13 guidelines/statements (Brott, 2011; Connolly, 2012; Rahme, 
2013; Biller, 2014; Kernan, 2014; Olin, 2014; Persu, 2014; Etminan, 
2015; Hemphill, 2015; Etminan, 2016; Searchfield, 2017; Powers, 
2018; Whelton, 2018) 2,3,48,75-84 
Prognosis - 1 Level 3 study (Olin, 2012)9 
- 7 level 4 studies (Corrin, 1981; Wells, 1982; Wesen, 1986; Stewart, 
1986; Liu, 2012; Pasquini, 2015; Hariott, 2017)14,33,36,39,45-47 
 
 
References 
 4 
 
1. Southerland AM, Meschia JF, Worrall BB. Shared associations of nonatherosclerotic, large-
vessel, cerebrovascular arteriopathies: considering intracranial aneurysms, cervical artery 
dissection, moyamoya disease and fibromuscular dysplasia. Curr Opin Neurol. 
2013;26(1):13-28. 
2. Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and 
critical unanswered questions: a scientific statement from the American Heart Association. 
Circulation. 2014;129(9):1048-1078. 
3. Persu A, Giavarini A, Touze E, et al. European consensus on the diagnosis and management 
of fibromuscular dysplasia. J Hypertens. 2014;32(7):1367-1378. 
4. Varennes L, Tahon F, Kastler A, et al. Fibromuscular dysplasia: what the radiologist should 
know: a pictorial review. Insights Imaging. 2015;6(3):295-307. 
5. Zhou W, Bush RL, Lin PL, Lumsden AB. Fibromuscular dysplasia of the carotid artery. J Am 
Coll Surg. 2005;200(5):807. 
6. Touzé E, Oppenheim C, Trystram D, et al. Fibromuscular dysplasia of cervical and 
intracranial arteries. Int J Stroke. 2010;5(4):296-305. 
7. Arning C, Grzyska U. Color Doppler imaging of cervicocephalic fibromuscular dysplasia. 
Cardiovasc Ultrasound. 2004;2:7. 
8. O'Connor S, Gornik HL, Froehlich JB, et al. Smoking and Adverse Outcomes in 
Fibromuscular Dysplasia: U.S. Registry Report. J Am Coll Cardiol. 2016;67(14):1750-1751. 
9. Olin JW, Froehlich J, Gu X, et al. The United States registry for fibromuscular dysplasia: 
results in the first 447 patients. Circulation. 2012;125(25):3182-3190. 
10. Saw J, Aymong E, Sedlak T, et al. Spontaneous coronary artery dissection: association with 
predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ 
Cardiovasc Interv. 2014;7(5):645-655. 
11. Saw J, Ricci D, Starovoytov A, Fox R, Buller CE. Spontaneous coronary artery dissection: 
prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center 
cohort. JACC Cardiovasc Interv. 2013;6(1):44-52. 
12. Schievink WI, Bjornsson J. Fibromuscular dysplasia of the internal carotid artery: a 
clinicopathological study. Clin Neuropathol. 1996;15(1):2-6. 
13. Sang CN, Whelton PK, Hamper UM, et al. Etiologic factors in renovascular fibromuscular 
dysplasia. A case-control study. Hypertension. 1989;14(5):472-479. 
14. Pasquini M, Trystram D, Nokam G, Gobin-Metteil MP, Oppenheim C, Touze E. Fibromuscular 
dysplasia of cervicocephalic arteries: Prevalence of multisite involvement and prognosis. Rev 
Neurol (Paris). 2015;171(8-9):616-623. 
15. Camuglia A, Manins V, Taylor A, Hengel C. Case Report and Review: Epicardial Coronary 
Artery Fibromuscular Dysplasia. Heart Lung Circ. 2008. 
16. Bofinger A, Hawley C, Fisher P, Daunt N, Stowasser M, Gordon R. Alpha-1-antitrypsin 
phenotypes in patients with renal arterial fibromuscular dysplasia. J HumHypertens. 
2000;14(2):91-94. 
17. Bofinger A, Hawley C, Fisher P, Daunt N, Stowasser M, Gordon R. Polymorphisms of the 
renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia. J 
HumHypertens. 2001;15(3):185-190. 
18. Poloskey SL, Kim E, Sanghani R, et al. Low yield of genetic testing for known vascular 
connective tissue disorders in patients with fibromuscular dysplasia. Vasc Med. 
2012;17(6):371-378. 
19. Kiando SR, Barlassina C, Cusi D, et al. Exome sequencing in seven families and gene-based 
association studies indicate genetic heterogeneity and suggest possible candidates for 
fibromuscular dysplasia. J Hypertens. 2015;33(9):1802-1810; discussion 1810. 
20. Kiando SR, Tucker NR, Castro-Vega LJ, et al. PHACTR1 Is a Genetic Susceptibility Locus for 
Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. PLoS Genet. 
2016;12(10):e1006367. 
21. Schievink WI, Puumala MR, Meyer FB, Raffel C, Katzmann JA, Parisi JE. Giant intracranial 
aneurysm and fibromuscular dysplasia in an adolescent with alpha 1-antitrypsin deficiency. J 
Neurosurg. 1996;85(3):503-506. 
22. Grimbert P, Fiquer-Kempf B, Coudol P, et al. [Genetic study of renal artery fibromuscular 
dysplasia]. ArchMal Coeur Vaiss. 1998;91(8):1069-1071. 
23. Marks SD, Gullett AM, Brennan E, et al. Renal FMD may not confer a familial hypertensive 
risk nor is it caused by ACTA2 mutations. Pediatr Nephrol. 2011;26(10):1857-1861. 
 5 
24. Gupta RM, Hadaya J, Trehan A, et al. A Genetic Variant Associated with Five Vascular 
Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. Cell. 2017;170(3):522-533 
e515. 
25. Fleisher GR, Buck BE, Cornfeld D. Primary intimal fibroplasia in a child with Down's 
syndrome. Am J Dis Child. 1978;132(7):700-703. 
26. Lancman M, Mesropian H, Serra P, Granillo R. Turner's syndrome, fibromuscular dysplasia, 
and stroke. Stroke. 1991;22(2):269-271. 
27. Schievink WI, Bjornsson J, Parisi JE, Prakash UB. Arterial fibromuscular dysplasia associated 
with severe alpha 1-antitrypsin deficiency. Mayo Clin Proc. 1994;69(11):1040-1043. 
28. Schievink WI, Bjornsson J, Piepgras DG. Coexistence of fibromuscular dysplasia and cystic 
medial necrosis in a patient with Marfan's syndrome and bilateral carotid artery dissections. 
Stroke. 1994;25(12):2492-2496. 
29. Solder B, Streif W, Ellemunter H, Mayr U, Jaschke W. Fibromuscular dysplasia of the internal 
carotid artery in a child with alpha-1-antitrypsin deficiency. DevMedChild Neurol. 
1997;39(12):827-829. 
30. Ganesh SK, Morissette R, Xu Z, et al. Clinical and biochemical profiles suggest fibromuscular 
dysplasia is a systemic disease with altered TGF-beta expression and connective tissue 
features. FASEB J. 2014;28(8):3313-3324. 
31. Boudin G, Guillard A, Romion A, et al. [Fibro-muscular dysplasia of the carotid and vertebral 
arteries. Considerations apropos of 37 cases]. Rev Otoneuroophtalmol. 1977;49(4):297-300. 
32. Collins GJ, Jr., Rich NM, Clagett GP, Spebar MJ, Salander JM. Fibromuscular dysplasia of 
the internal carotid arteries. Clinical experience and follow-up. AnnSurg. 1981;194(1):89-96. 
33. Corrin LS, Sandok BA, Houser OW. Cerebral ischemic events in patients with carotid artery 
fibromuscular dysplasia. ArchNeurol. 1981;38(10):616-618. 
34. Effeney DJ, Ehrenfeld WK, Stoney RJ, Wylie EJ. Why operate on carotid fibromuscular 
dysplasia? ArchSurg. 1980;115(11):1261-1265. 
35. Ehrenfeld WK, Wylie EJ. Fibromuscular dysplasia of the internal carotid artery. ArchSurg. 
1974;109(5):676-681. 
36. Harriott AM, Zimmerman E, Singhal AB, Jaff MR, Lindsay ME, Rordorf GA. Cerebrovascular 
fibromuscular dysplasia: The MGH cohort and literature review. Neurol Clin Pract. 
2017;7(3):225-236. 
37. Houser OW, Baker HL, Jr., Sandok BA, Holley KE. Cephalic arterial fibromuscular dysplasia. 
Radiology. 1971;101(3):605-611. 
38. Kelly TF, Morris GC, Jr. Arterial fibromuscular disease. Observations on pathogenesis and 
surgical management. Am J Surg. 1982;143:232-236. 
39. Liu CH, Wu D, Chin SC, et al. Cervicocranial fibromuscular dysplasia in Taiwanese ischemic 
stroke patients. Eur Neurol. 2012;67(3):129-135. 
40. Manelfe C, Clarisse J, Fredy D, André JM, Crouzet G. Dysplasies fibromusculaires des 
artères cervico-céphaliques. J Neuroradiol. 1974;1:149-231. 
41. Mettinger KL, Ericson K. Fibromuscular dysplasia and the brain. I. Observations on 
angiographic, clinical and genetic characteristics. Stroke. 1982;13(1):46-52. 
42. Moreau P, Albat B, Thevenet A. Fibromuscular dysplasia of the internal carotid artery: long-
term surgical results. J CardiovascSurg(Torino). 1993;34(6):465-472. 
43. Osborn AG, Anderson RE. Angiographic spectrum of cervical and intracranial fibromuscular 
dysplasia. Stroke. 1977;8(5):617-626. 
44. So EL, Toole JF, Dalal P, Moody DM. Cephalic fibromuscular dysplasia in 32 patients: clinical 
findings and radiologic features. ArchNeurol. 1981;38(10):619-622. 
45. Stewart MT, Moritz MW, Smith RB, III, Fulenwider JT, Perdue GD. The natural history of 
carotid fibromuscular dysplasia. J VascSurg. 1986;3(2):305-310. 
46. Wells RP, Smith RR. Fibromuscular dysplasia of the internal carotid artery: a long term follow-
up. Neurosurgery. 1982;10(1):39-43. 
47. Wesen CA, Elliott BM. Fibromuscular dysplasia of the carotid arteries. Am J Surg. 
1986;151(4):448-451. 
48. Biller J, Sacco RL, Albuquerque FC, et al. Cervical arterial dissections and association with 
cervical manipulative therapy: a statement for healthcare professionals from the american 
heart association/american stroke association. Stroke. 2014;45(10):3155-3174. 
49. Debette S. Pathophysiology and risk factors of cervical artery dissection: what have we learnt 
from large hospital-based cohorts? Curr Opin Neurol. 2014;27(1):20-28. 
50. O'Connor SC, Poria N, Gornik HL. Fibromuscular dysplasia: an update for the headache 
clinician. Headache. 2015;55(5):748-755. 
 6 
51. Plouin PF, Baguet JP, Thony F, et al. High Prevalence of Multiple Arterial Bed Lesions in 
Patients With Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and 
Cervical Artery Dysplasia). Hypertension. 2017;70:652-658. 
52. Choi PM, Singh D, Trivedi A, et al. Carotid Webs and Recurrent Ischemic Strokes in the Era 
of CT Angiography. AJNR Am J Neuroradiol. 2015;36(11):2134-2139. 
53. Cloft HJ, Kallmes DF, Kallmes MH, Goldstein JH, Jensen ME, Dion JE. Prevalence of 
cerebral aneurysms in patients with fibromuscular dysplasia: a reassessment. J Neurosurg. 
1998;88(3):436-440. 
54. Joux J, Boulanger M, Jeannin S, et al. Association Between Carotid Bulb Diaphragm and 
Ischemic Stroke in Young Afro-Caribbean Patients: A Population-Based Case-Control Study. 
Stroke. 2016;47:2641-2644. 
55. Joux J, Chausson N, Jeannin S, et al. Carotid-bulb atypical fibromuscular dysplasia in young 
Afro-Caribbean patients with stroke. Stroke. 2014;45(12):3711-3713. 
56. Green R, Gu X, Kline-Rogers E, et al. Differences between the pediatric and adult 
presentation of fibromuscular dysplasia: results from the US Registry. Pediatr Nephrol. 
2016;31(4):641-650. 
57. Kadian-Dodov D, Gornik HL, Gu X, et al. Dissection and Aneurysm in Patients With 
Fibromuscular Dysplasia: Findings From the U.S. Registry for FMD. J Am Coll Cardiol. 
2016;68(2):176-185. 
58. Kirton A, Crone M, Benseler S, et al. Fibromuscular dysplasia and childhood stroke. Brain. 
2013;136(Pt 6):1846-1856. 
59. Lather HD, Gornik HL, Olin JW, et al. Prevalence of Intracranial Aneurysm in Women With 
Fibromuscular Dysplasia: A Report From the US Registry for Fibromuscular Dysplasia. JAMA 
Neurol. 2017;74(9):1081-1087. 
60. Haussen DC, Grossberg JA, Bouslama M, et al. Carotid Web (Intimal Fibromuscular 
Dysplasia) Has High Stroke Recurrence Risk and Is Amenable to Stenting. Stroke. 
2017;48(11):3134-3137. 
61. Belen D, Bolay H, Firat M, Akpinar G, Bertan V. Unusual appearance of intracranial 
fibromuscular dysplasia. A case report. Angiology. 1996;47(6):627-632. 
62. Kubis N, Von LD, Petitjean C, et al. Thrombotic carotid megabulb: fibromuscular dysplasia, 
septae, and ischemic stroke. Neurology. 1999;52(4):883-886. 
63. Lenck S, Labeyrie MA, Saint-Maurice JP, Tarlov N, Houdart E. Diaphragms of the carotid and 
vertebral arteries: an under-diagnosed cause of ischaemic stroke. Eur J Neurol. 
2014;21(4):586-593. 
64. Nakamura M, Rosahl SK, Vorkapic P, Forster C, Samii M. De novo formation of an aneurysm 
in a case of unusual intracranial fibromuscular dysplasia. Clin NeurolNeurosurg. 
2000;102(4):259-264. 
65. Ukkola-Pons E, Sadik JC, Champtiaux N, et al. [Free floating thrombus on carotid megabulb 
or suspended bulb: what kind of dysplasia?]. Rev Neurol (Paris). 2012;168(1):53-56. 
66. De Groote M, Van der Niepen P, Hemelsoet D, et al. Fibromuscular dysplasia - results of a 
multicentre study in Flanders. Vasa. 2017;46(3):211-218. 
67. Choi PM, Menon BK, Demchuk AM. Carotid web and stroke. Eur J Neurol. 2014;21(6):e53. 
68. van de Nes JA, Bajanowski T, Trubner K. Fibromuscular dysplasia of the basilar artery: an 
unusual case with medico-legal implications. Forensic Sci Int. 2007;173(2-3):188-192. 
69. Debette S, Compter A, Labeyrie MA, et al. Epidemiology, pathophysiology, diagnosis, and 
management of intracranial artery dissection. Lancet Neurol. 2015;14(6):640-654. 
70. Larsson SC, King A, Madigan J, Levi C, Norris JW, Markus HS. Prognosis of carotid 
dissecting aneurysms: Results from CADISS and a systematic review. Neurology. 
2017;88(7):646-652. 
71. Schirmer CM, Atalay B, Malek AM. Endovascular recanalization of symptomatic flow-limiting 
cervical carotid dissection in an isolated hemisphere. Neurosurg Focus. 2011;30(6):E16. 
72. Touze E, Randoux B, Meary E, Arquizan C, Meder JF, Mas JL. Aneurysmal forms of cervical 
artery dissection : associated factors and outcome. Stroke. 2001;32(2):418-423. 
73. Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. 
Lancet neurology. 2009;8(7):668-678. 
74. Hage ZA, Behbahani M, Amin-Hanjani S, Charbel FT. Carotid bypass for carotid occlusion. 
Curr Atheroscler Rep. 2015;17(7):36. 
75. Brott TG, Halperin JL, Abbara S, et al. 2011 
ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on 
the management of patients with extracranial carotid and vertebral artery disease: executive 
 7 
summary. A report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines, and the American Stroke Association, 
American Association of Neuroscience Nurses, American Association of Neurological 
Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of 
Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for 
Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of 
NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular 
Surgery. Circulation. 2011;124(4):489-532. 
76. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of 
aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the 
American Heart Association/american Stroke Association. Stroke. 2012;43(6):1711-1737. 
77. Rahme RJ, Aoun SG, McClendon J, Jr., El Ahmadieh TY, Bendok BR. Spontaneous cervical 
and cerebral arterial dissections: diagnosis and management. Neuroimaging Clin N Am. 
2013;23(4):661-671. 
78. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients 
with stroke and transient ischemic attack: a guideline for healthcare professionals from the 
American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236. 
79. Hemphill JC, 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of 
Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the 
American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-2060. 
80. Etminan N, Brown RD, Jr., Beseoglu K, et al. The unruptured intracranial aneurysm treatment 
score: a multidisciplinary consensus. Neurology. 2015;85(10):881-889. 
81. Etminan N, Rinkel GJ. Unruptured intracranial aneurysms: development, rupture and 
preventive management. Nat Rev Neurol. 2016;12(12):699-713. 
82. Searchfield GD, Durai M, Linford T. A State-of-the-Art Review: Personalization of Tinnitus 
Sound Therapy. Front Psychol. 2017;8:1599. 
83. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of 
Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the 
American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. 
84. Whelton PK, Carey RM, Aronow WS, et al. 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A 
Report of the American College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. 
 
 8 
eTable 2 – Summary of the largest (≥15 patients) case studies of patients with cerebrovascular fibromuscular dysplasia  
Study,ref N patients 
Mean 
(range) 
age, yrs 
Characteristics, % Setting  Clinical presentation, % (non exclusive) IC FMD, % 
Women Smoking HTN  TIA IS$ ICH SAH CeAD$ Other symptoms 
Tinnitus 
or bruit* 
Headaches
* UIA 
String of 
beads 
Houser, 
19711 52 
NR 
(12-78) 94 NR NR Radiology 8 12 2 17 NR 25 0 NR 6 0 
Ehrenfield
, 19742 20 
52 
(NR) 90 NR NR Surgery 35 35 0 9 NR 26 15 NR NR NR 
Manelfe, 
19743 70 
54 
(17-75) 74 NR 31 Radiology 13 41 NR 40 4 13 17 14 NR       83 
Osborn, 
19774 25 
46 
(4-71) 80 NR NR Radiology 40 24 0 32 NR 8 4 NR 30 20 
Boudin, 
19775 37 
47 
(NR) 85 NR NR 
Neurology 
Surgery 70 0 0 NR 14 16 NR NR NR 
Effeney, 
19806 76 
58 
(27-83) 97 NR NR Surgery 42 22 0 0 NR 6 23 NR 13 0 
Corrin, 
19817 79 
58 
(18-76) 94 NR 29 Neurology 8 9 0 13 NR 61 8 NR NR 0 
So,  
19818 32 
57 
(34-78) 100 NR NR Neurology 28 28 0 16 NR 16 13 NR 22 9 
Collins, 
19819 18 
60 
(40-80) 100 NR NR Surgery 50 0 0 NR 44 39 NR 5.5 NR 
Wells, 
198210 17 
58 
(36-74) 94 NR NR Surgery 53 0 0 0 NR 35 29 38 NR NR 
Mettinger, 
198211 37 
48 
(24-70) 81 NR NR Radiology 11 8 8 49 NR 24 38 78 49 2.7 
Kelly, 
198212 40 
NR 
(38-78) 85 NR NR Surgery 30 10 0 0 NR NR 30 43 NR NR 
Stewart, 
198613 49 
58 
(29-82) 98 NR NR Surgery 35 27 6 NR NR 42 6 4 8 NR 
Wesen, 
198614 30 
59 
(20-77) 77 47 40 Surgery 53 10 0 3 NR 26 NR NR NR NR 
Moreau, 
199315 58 
55 
(20-76) 60 NR 25 Surgery 43 0 0 NR 53 NR 22 NR NR 
Liu,  
201216 19 
46 
(32-64) 53 NR NR Radiology 5 95 0 0 74 0 NR 16 5 16 
Pasquini, 
201517 36 57 89 36 39 Neurology 17 47 0 5.6 25 0 5.6 NR 5.6 25 
Hariott, 
201718 81 
53 
(19-83) 96 49 68 
Vascular 
Medicine 24 7 0 4 35 36 30/43 52 NR NR 
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HTN : hypertension – TIA : transient ischaemic attack (including amaurosis fugax) – IS : ischaemic stroke – ICH : intracranial 
haemorrhage – SAH : subarachnoid haemorrhage – UIA : unruptured intracranial aneurysm –  CeAD : cervical artery dissection – IC 
FMD: intracranial fibromuscular dysplasia - NR : not reported – NC : not clear – * symptoms reported at any time (where available) – $ 
patients with IS and CeAD are included in both columns. 
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eTable 3 – Genetic investigations and syndromic reports of fibromuscular 
dysplasia1 
 
Gene/ syndrome Renal fibromuscular dysplasia Cerebrovascular 
fibromuscular 
dysplasia 
ACE  Insertion allele associated2 n/a 
AT1R No association2 n/a 
AGT No association2 n/a 
Elastin No association3 n/a 
Alpha-1-antitripsin No association
4 
Case report5 Case reports
6-9 
ACTA2 No association10 No association11 
TGFβR1 and  Variants of unknown significance identified No association
11 
TGFβR2 n/a No association11 
collagen 3A1 n/a No association11 
SMAD3 n/a No association11 
Fibrillin (Marfan syndrome) n/a No association 
11 
Case report12 
Down Syndrome Case report13 n/a 
Turner Syndrome n/a Case report14 
Neurofibromatosis I Case report15 n/a 
 
n/a - not available 
ACE: angiotensin I Converting Enzyme 
AT1R: angiotensin II type 1 receptor 
AGT: Angiotensinogen 
ACTA2: smooth muscle alpha (α)-2 actin 
TGFβR: transforming growth factor, beta-receptor  
SMAD3: mothers against decapentaplegic homolog 3 
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eTable 4 – Prognosis of patients with cerebrovascular fibromuscular dysplasia (FMD) 
 
Study,ref N 
patients 
Clinical presentation (%) Follow-up 
(years) 
Cerebrovascular events during follow-up, n (%/year) 
TIA/ischemic 
stroke 
ICH SAH CeAD TIA/ischemic 
stroke 
ICH SAH CeAD FMD progression 
Corrin, 
19811 79 15 0 13 NR 5 3 (0.76) NR NR NR NR 
Wells, 
19822 16 53 0 0 NR 3.8 2 (3.29) NR NR NR 0 
Wesen, 
19863 30 63 NR 3 NR 1.8 2 (3.70) NR NR NR NR 
Stewart, 
19864 35 61 6 6 NR 6.5 0 0 NR 0 NR 
Liu,  
20125 19 100 0 0 74 2.2 0 0 NR NR NR 
Pasquini, 
20156 36 64 0 6 25 3.5 4 (3.18) 
1 
(0.79) NR 
1 
(0.79) 
1 (0.79) 
(stenosis) 
Hariott, 
20177 67 23 0 4 35 2.4 1 (0.62) 0 NR 0 
1 (0.62) (new 
intracranial aneurysm) 
 
TIA: transient ischemic attack – ICH: Intracranial hemorrhage – SAH: subarahnoid hemorrhage – CeAD: Cervical Artery dissection – NR: not reported 
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eFigure 1 – PRISMA flow diagram describing identification, screening, eligibility, and inclusion of studies in the systematic 
review 
 
Titles screened (n=2795) 
IDENTIFICATION
SCREENING
ELIGIBILITY
Excluded (n=2507) 
Excluded (n=117):
-Outcomes did not meet our inclusion 
criteria (n=111)
- Other reports of included studies (n=6)
INCLUSION 
Pubmed (n=2788)
Abstracts screened (n=288) 
Excluded (n=94) 
Systematic review (n=84)
Hand searching (n=16)
Unique studies after duplicates removed (n=2795)
Full-texts screened (n=194) Full-texts identified from bibliography screening (n=7)
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eFigure 2 – Mild cervical and focal form of fibromuscular dysplasia (FMD)  
 
A. Lateral conventional angiography of a right internal carotid artery (black arrow).  
B. Conventional angiography of a left vertebral artery (black arrow).  
C. 3D T1 contrast enhanced MRI in maximum intensity projection reconstruction in coronal view of a bilateral focal form of 
cervical FMD (white dotted arrow).  
D. Conventional angiography of a left cervical internal carotid artery in a patient with a unifocal FMD lesion (black arrow head).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 15 
eFigure 3 – Illustrative clinical case of diffuse fibromuscular dysplasia (FMD) in 
a young woman 
 
46-year old woman, with acute headache and confusion admitted with a CT scan showing a severe subarachnoid bleeding 
(Fisher IV) due to the rupture of a large dissecting aneurysm of the proximal segment of the right middle cerebral artery (A, 
white arrow). The patient presented a diffuse FMD which on internal carotid (B, white dotted arrow) and vertebral (C, black 
arrow head) arteries. Renal artery angiography also showed FMD on the left (D, black arrow). The patient was successfully 
treated by a combination of endovascular and neurosurgical intervention.  
 
 
 
 
 
 
 
 
 
 
 
Supplemental	Figure	1	-	Mild	cervical	and	focal	form	of	FMD		A.	Lateral	conventional	angiography	of	a	right	internal	carotid	artery	(black	arrow).	B.	Conventional	angiography	of	a	left	vertebral	artery	(black	arrow).	C.	3D	T1	contrast	enhanced	MRI	in	maximum	intensity	projection	reconstruction	in	coronal	view	of	a	bilateral	focal	form	of	cervical	FMD	(white	dotted	arrow).	D.	Conventional	angiography	of	a	left	cervical	internal	carotid	artery	in	a	patient	with	a	unifocal	FMD	lesion	(black	arrow	head).		
		
																	
	 	
Supplemental	Figure	2	–	Illustrative	clinical	case	of	diffuse	FMD	in	a	young	
woman.			46-year	old	woman,	with	acute	headache	and	confusion	admitted	with	a	CT	scan	showing	a	severe	subarachnoid	bleeding	(Fisher	IV)	due	to	the	rupture	of	a	large	dissecting	aneurysm	of	the	proximal	segment	of	the	right	middle	cerebral	artery	(A,	white	arrow).	The	patient	presented	a	diffuse	FMD	which	on	internal	carotid	(B,	white	dotted	arrow)	and	vertebral	(C,	black	arrow	head)	arteries.	Renal	artery	angiography	also	showed	FMD	on	the	left	(D,	black	arrow).	The	patient	was	successfully	treated	by	a	combination	of	endovascular	and	neurosurgical	intervention.		
		
			
Supplemental Table 1 – Evidence level of studies evaluating epidemiology, genetic risk, presenting 
manifestations, cerebrovascular clinical manifestations, management and prognosis in 
neurological manifestations of fibromuscular dysplasia: summary of systematic review according 
to the Oxford Centre for Evidence-based Medicine.  
Quality Rating Scheme for Studies and Other Evidence according to the Oxford Centre for 
Evidence-based Medicine.  
1. Properly powered and conducted randomized clinical trial; systematic review with meta-analysis 
2. Well-designed controlled trial without randomization; prospective comparative cohort trial 
3. Case-control studies; retrospective cohort study 
4. Case series with or without intervention; cross-sectional study 
5. Opinion of respected authorities; case reports 
 
Manuscript sections Number of studies included by evidence level 
Classification and 
diagnostic criteria 
- 1 Level 4 study (Southerland, 2013)1 
- 2 guidelines/statements (Persu, 2014; Olin, 2014)2,3  
Imaging - 3 level 4 studies (Touzé, 2010; Varennes, 2015; Zhou, 2005)4-6 
- 1 level 5 study (Arning, 2004)7 
- 1 guideline/statement (Persu, 2014)3 
Epidemiology - 7 Level 3 studies (Schievink, 1996; Olin, 2012; Saw, 2013; Saw, 2014; 
O’Connor, 2016; Plouin, 2017)8-13 
- 2 level 4 studies (Pasquini, 2015; Southerland, 2013)1,14  
- 2 Level 5 studies (Touzé, 2010;Camuglia, 2008)6,15  
- 1 guideline/statement2 
Genetic risk - 5 Level 3 studies (Bofinger, 2000; Bofinger, 2001; Poloskey, 2012; 
Kiando, 2015; Kiando, 2016)16-20  
- 5 level 4 studies (Schievink, 1996; Grimbert, 1998; Marks, 2011; 
Southerland, 2013; Gupta, 2017)1,21-24 
- 7 Level 5 study (Fleischer, 1978; Kousseff, 1989; Lancman, 1991; 
Schievink, 1994; Schievink, 1994; Solder, 1997; Ganesh, 2014)25-30  
Presenting and 
cerebrovascular clinical 
manifestations 
- 33 Level 3 studies (Houser, 1971; Ehrenfield, 1974; Manelfe, 1974; 
Osborn, 1977; Boudin, 1977; Effeney, 1980; Corrin, 1981; So, 1981; 
Collins, 1981; Wells, 1982; Mettinger, 1982; Kelly, 1982; Stewart, 1986; 
Wesen, 1986; Moreau, 1993; Cloft, 1998; Liu, 2012; Olin, 2012;  Kirton, 
2013; Debette, 2014; Béjot 2014; Joux, 2014; O’Connor, 2015; Pasquini, 
2015;  Choi, 2015;  Kadian-Dodov, 2016; Joux, 2016; Green 2016; Hariott, 
2017; Plouin, 2017; Haussen, 2017;  Lather, 2017; de Groote, 
2017)8,9,14,31-60 
- 8 Level 4 studies (Belen, 1996; Faggioli, 1996; Nakamura, 2000; Kubis, 
1999; Southerland, 2013; Lenck, 2014; Touzé, 2010; Ukkola-Pons, 
2012)1,6,36,61-66  
- 2 Level 5 studies (Choi, 2014; van de Nes, 2017)67,68 
Management - 3 level 3 studies (O’Connor, 2015; Debette, 2014; Larsson, 2017)50,69,70  
- 2 level 4 studies (Touzé, 2001; Schirmer, 2011)71,72 
- 3 Level 5 studies (Debette, 2009; Debette, 2015; Hage, 2015)69,73,74 
- 13 guidelines/statements (Brott, 2011; Connolly, 2012; Rahme, 2013; 
Biller, 2014; Kernan, 2014; Olin, 2014; Persu, 2014; Etminan, 2015; 
Hemphill, 2015; Etminan, 2016; Searchfield, 2017; Powers, 2018; 
Whelton, 2018) 2,3,48,75-84 
Prognosis - 1 Level 3 study (Olin, 2012)9 
- 7 level 4 studies (Corrin, 1981; Wells, 1982; Wesen, 1986; Stewart, 
1986; Liu, 2012; Pasquini, 2015; Hariott, 2017)14,33,36,39,45-47 
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Supplemental	table	2–	Summary	of	the	largest	(≥15	patients)	case	studies	of	cervico-cephalic	fibromuscular	dysplasia	(FMD)		
Study,ref N patients 
Mean (range) 
age, yrs 
Characteristics, % 
Setting 
 Clinical presentation, % (non exclusive) IC FMD, % 
Females Smoking HTN TIA IS$ ICH SAH CeAD$ 
Miscellaneou
s symptoms 
Tinnitus 
or bruit* 
Headaches
* UIA 
String of 
beads 
Houser, 
19711 52 
NR 
(12-78) 94 NR NR Radiology 8 12 2 17 NR 25 0 NR 6 0 
Ehrenfield, 
19742 20 
52 
(NR) 90 NR NR Surgery 35 35 0 9 NR 26 15 NR NR NR 
Manelfe, 
19743 70 
54 
(17-75) 74 NR 31 Radiology 13 41 NR 40 4 13 17 14 NR       83 
Osborn, 
19774 25 
46 
(4-71) 80 NR NR Radiology 40 24 0 32 NR 8 4 NR 30 20 
Boudin, 
19775 37 
47 
(NR) 85 NR NR 
Neurology 
Surgery 70 0 0 NR 14 16 NR NR NR 
Effeney, 
19806 76 
58 
(27-83) 97 NR NR Surgery 42 22 0 0 NR 6 23 NR 13 0 
Corrin, 19817 79 58 (18-76) 94 NR 29 Neurology 8 9 0 13 NR 61 8 NR NR 0 
So, 19818 32 57 (34-78) 100 NR NR Neurology 28 28 0 16 NR 16 13 NR 22 9 
Collins, 19819 18 60 (40-80) 100 NR NR Surgery 50 0 0 NR 44 39 NR 5.5 NR 
Wells, 198210 17 58 (36-74) 94 NR NR Surgery 53 0 0 0 NR 35 29 38 NR NR 
Mettinger, 
198211 37 
48 
(24-70) 81 NR NR Radiology 11 8 8 49 NR 24 38 78 49 2.7 
Kelly, 198212 40 NR (38-78) 85 NR NR Surgery 30 10 0 0 NR NR 30 43 NR NR 
Stewart, 
198613 49 
58 
(29-82) 98 NR NR Surgery 35 27 6 NR NR 42 6 4 8 NR 
Wesen, 
198614 30 
59 
(20-77) 77 47 40 Surgery 53 10 0 3 NR 26 NR NR NR NR 
Moreau, 
199315 58 
55 
(20-76) 60 NR 25 Surgery 43 0 0 NR 53 NR 22 NR NR 
Liu, 201216 19 46 (32-64) 53 NR NR Radiology 5 95 0 0 74 0 NR 16 5 16 
Pasquini, 
201517 36 57 89 36 39 Neurology 17 47 0 5.6 25 0 5.6 NR 5.6 25 
Hariott, 
201718 81 
53 
(19-83) 96 49 68 
Vascular 
Medicine 24 7 0 4 35 36 30/43 52 NR NR 
HTN : hypertension – TIA : transient ischaemic attack (including amaurosis fugax) – IS : ischaemic stroke – ICH : intracranial haemorrhage – SAH : subarachnoid 
haemorrhage – UIA : unruptured intracranial aneurysm –  CeAD : cervical artery dissection – IC FMD: intracranial FMD - NR : not reported – NC : not clear – * symptoms 
reported at any time (where available) – $ patients with IS and CeAD are included in both columns. 
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Supplemental table 3: Genetic investigations and syndromic reports of fibromuscular 
dysplasia (FMD).1 
 
Gene/ syndrome Renal Cervico-cephalic 
FMD 
ACE  Insertion allele associated2 n/a 
AT1R No association2 n/a 
AGT No association2 n/a 
Elastin No association3 n/a 
Alpha-1-antitripsin No association4 
Case report5 
Case reports6-9 
ACTA2 No association10 No association11 
TGFβR1 and  Variants of unknown 
significance identified 
No association11 
TGFβR2 n/a No association11 
collagen 3A1 n/a No association11 
SMAD3 n/a No association11 
Fibrillin (Marfan syndrome) n/a No association 11 
Case report12 
Down Syndrome Case report13 n/a 
Turner Syndrome n/a Case report14 
Neurofibromatosis I Case report15 n/a 
n/a - not available 
ACE: angiotensin I Converting Enzyme 
AT1R: angiotensin II type 1 receptor 
AGT: Angiotensinogen 
ACTA2: smooth muscle alpha (α)-2 actin 
TGFβR: transforming growth factor, beta-receptor  
SMAD3: mothers against decapentaplegic homolog 3 		
	 	
References		1.	 Southerland	AM,	Meschia	JF,	Worrall	BB.	Shared	associations	of	nonatherosclerotic,	large-vessel,	cerebrovascular	arteriopathies:	considering	intracranial	aneurysms,	cervical	artery	dissection,	moyamoya	disease	and	fibromuscular	dysplasia.	Curr	Opin	Neurol.	2013;26(1):13-28.	2.	 Bofinger	A,	Hawley	C,	Fisher	P,	Daunt	N,	Stowasser	M,	Gordon	R.	Polymorphisms	of	the	renin-angiotensin	system	in	patients	with	multifocal	renal	arterial	fibromuscular	dysplasia.	J	HumHypertens.	2001;15(3):185-190.	3.	 Grimbert	P,	Fiquer-Kempf	B,	Coudol	P,	et	al.	[Genetic	study	of	renal	artery	fibromuscular	dysplasia].	ArchMal	Coeur	Vaiss.	1998;91(8):1069-1071.	4.	 Perdu	J,	Gimenez-Roqueplo	AP,	Boutouyrie	P,	et	al.	Alpha1-antitrypsin	gene	polymorphisms	are	not	associated	with	renal	arterial	fibromuscular	dysplasia.	J	
Hypertens.	2006;24(4):705-710.	5.	 Bofinger	A,	Hawley	C,	Fisher	P,	Daunt	N,	Stowasser	M,	Gordon	R.	Alpha-1-antitrypsin	phenotypes	in	patients	with	renal	arterial	fibromuscular	dysplasia.	J	
HumHypertens.	2000;14(2):91-94.	6.	 Solder	B,	Streif	W,	Ellemunter	H,	Mayr	U,	Jaschke	W.	Fibromuscular	dysplasia	of	the	internal	carotid	artery	in	a	child	with	alpha-1-antitrypsin	deficiency.	DevMedChild	
Neurol.	1997;39(12):827-829.	7.	 Schievink	WI,	Bjornsson	J.	Fibromuscular	dysplasia	of	the	internal	carotid	artery:	a	clinicopathological	study.	Clin	Neuropathol.	1996;15(1):2-6.	8.	 Schievink	WI,	Meyer	FB,	Parisi	JE,	Wijdicks	EF.	Fibromuscular	dysplasia	of	the	internal	carotid	artery	associated	with	alpha1-antitrypsin	deficiency.	Neurosurgery.	1998;43(2):229-233.	9.	 Schievink	WI,	Bjornsson	J,	Parisi	JE,	Prakash	UB.	Arterial	fibromuscular	dysplasia	associated	with	severe	alpha	1-antitrypsin	deficiency.	Mayo	Clin	Proc.	1994;69(11):1040-1043.	10.	 Marks	SD,	Gullett	AM,	Brennan	E,	et	al.	Renal	FMD	may	not	confer	a	familial	hypertensive	risk	nor	is	it	caused	by	ACTA2	mutations.	Pediatr	Nephrol.	2011;26(10):1857-1861.	11.	 Poloskey	SL,	Kim	E,	Sanghani	R,	et	al.	Low	yield	of	genetic	testing	for	known	vascular	connective	tissue	disorders	in	patients	with	fibromuscular	dysplasia.	Vasc	Med.	2012;17(6):371-378.	12.	 Schievink	WI,	Bjornsson	J,	Piepgras	DG.	Coexistence	of	fibromuscular	dysplasia	and	cystic	medial	necrosis	in	a	patient	with	Marfan's	syndrome	and	bilateral	carotid	artery	dissections.	Stroke.	1994;25(12):2492-2496.	13.	 Fleisher	GR,	Buck	BE,	Cornfeld	D.	Primary	intimal	fibroplasia	in	a	child	with	Down's	syndrome.	Am	J	Dis	Child.	1978;132(7):700-703.	14.	 Lancman	M,	Mesropian	H,	Serra	P,	Granillo	R.	Turner's	syndrome,	fibromuscular	dysplasia,	and	stroke.	Stroke.	1991;22(2):269-271.	15.	 Kousseff	BG,	Gilbert-Barness	EF.	"Vascular	neurofibromatosis"	and	infantile	gangrene.	Am	J	Med	Genet.	1989;34(2):221-226.		
Supplemental table 4 – Prognosis of patients with cervico-cephalic fibromuscular dysplasia (FMD): risk of cerebrovascular events 
 
Study,ref N 
patients 
Clinical presentation (%) Follow-up 
(years) 
Cerebrovascular events during follow-up n (%/year) 
TIA/ischemic 
stroke 
ICH SAH CeAD TIA/ischemic 
stroke 
ICH SAH CeAD FMD progression 
Corrin, 
19811 79 15 0 13 NR 5 3 (0.76) NR NR NR NR 
Wells, 
19822 16 53 0 0 NR 3.8 2 (3.29) NR NR NR 0 
Wesen, 
19863 30 63 NR 3 NR 1.8 2 (3.70) NR NR NR NR 
Stewart, 
19864 35 61 6 6 NR 6.5 0 0 NR 0 NR 
Liu,  
20125 19 100 0 0 74 2.2 0 0 NR NR NR 
Pasquini, 
20156 36 64 0 6 25 3.5 4 (3.18) 
1 
(0.79) NR 
1 
(0.79) 
1 (0.79) 
(stenosis) 
Hariott, 
20177 67 23 0 4 35 2.4 1 (0.62) 0 NR 0 
1 (0.62) (new 
intracranial aneurysm) 
TIA: transient ischemic attack – ICH: Intracranial hemorrhage – SAH: subarahnoid hemorrhage – CeAD: Cervical Artery dissection – NR: not reported 
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